![Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ](https://www.bmj.com/content/bmj/382/bmj-2022-074325/F6.medium.jpg)
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ
![Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet](https://www.thelancet.com/cms/attachment/55458d8a-6e53-43a3-abb0-e72e5acba138/gr1.gif)
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
![Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health](https://www.thelancet.com/cms/attachment/b7470a81-2935-4740-9fb4-c532d912c682/gr1_lrg.gif)
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health
![Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant | Signal Transduction and Targeted Therapy Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant | Signal Transduction and Targeted Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41392-022-01062-3/MediaObjects/41392_2022_1062_Fig1_HTML.png)
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant | Signal Transduction and Targeted Therapy
![Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_754645_16903578774359511.jpg)
Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes
Sano y salvo on X: "Declaración conjunta de la @EMA_News y el @ECDC_EU sobre la posibilidad de usar dos vacunas #COVID19 diferentes, tanto para las dos primeras dosis como para la tercera
![Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens - ScienceDirect Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2666634021002890-fx1.jpg)
Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens - ScienceDirect
![Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study - The Lancet Respiratory Medicine Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/asset/b9c057e0-e68d-4608-9700-73b19be518ae/gr1.jpg)
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study - The Lancet Respiratory Medicine
![Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/ec8132af-622c-4cda-bd8d-1f61c6ca2606/gr1_lrg.jpg)
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe
![Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ](https://www.bmj.com/content/bmj/378/bmj-2022-070483/F2.large.jpg)
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ
![Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2 Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2](https://www.mdpi.com/vaccines/vaccines-10-02146/article_deploy/html/images/vaccines-10-02146-g001a.png)
Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
![Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine - ScienceDirect Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332222000385-ga1.jpg)
Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine - ScienceDirect
Strategies and safety considerations of booster vaccination in COVID-19 | Biomolecules and Biomedicine
![Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 - The Lancet Infectious Diseases Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/4f775784-4453-4c08-98f1-01483f865da7/gr1_lrg.jpg)
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 - The Lancet Infectious Diseases
![Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination | Nature Medicine Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01705-6/MediaObjects/41591_2022_1705_Fig1_HTML.png)
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination | Nature Medicine
![Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2 Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2](https://pub.mdpi-res.com/vaccines/vaccines-10-02146/article_deploy/html/images/vaccines-10-02146-g002.png?1671532641)
Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
![Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination | Nature Medicine Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01449-9/MediaObjects/41591_2021_1449_Fig1_HTML.png)
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination | Nature Medicine
![Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial - The Lancet Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial - The Lancet](https://www.thelancet.com/cms/asset/f37e5492-b6e5-43dd-9400-1478e6cbe180/gr1.jpg)
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial - The Lancet
![Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/asset/3b4eb078-d7dd-4a37-98ea-553c444f2a49/gr1.jpg)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
![Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine](https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2021/10/shutterstock_1901384401-1.jpg)